IN2012DN03294A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03294A
IN2012DN03294A IN3294DEN2012A IN2012DN03294A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A IN 3294DEN2012 A IN3294DEN2012 A IN 3294DEN2012A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A
Authority
IN
India
Prior art keywords
epitope
candidate
cross
binding agent
specific binding
Prior art date
Application number
Other languages
English (en)
Inventor
J Chang Gwongjen
D Crill Wayne
Original Assignee
Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And filed Critical Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Publication of IN2012DN03294A publication Critical patent/IN2012DN03294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IN3294DEN2012 2004-07-27 2005-07-27 IN2012DN03294A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59189804P 2004-07-27 2004-07-27
PCT/US2005/026672 WO2006025990A2 (en) 2004-07-27 2005-07-27 Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use

Publications (1)

Publication Number Publication Date
IN2012DN03294A true IN2012DN03294A (cs) 2015-10-23

Family

ID=36000491

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3294DEN2012 IN2012DN03294A (cs) 2004-07-27 2005-07-27

Country Status (6)

Country Link
US (3) US7906292B2 (cs)
EP (1) EP1784487B1 (cs)
AT (1) ATE521627T1 (cs)
CA (1) CA2576798C (cs)
IN (1) IN2012DN03294A (cs)
WO (1) WO2006025990A2 (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524975T3 (es) 2009-07-31 2014-12-16 Ge Healthcare Bio-Sciences Corp. Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células
EP2731961A4 (en) * 2011-07-12 2015-12-09 Us Government IDENTIFICATION OF A WEST NIL VIRUS CD4 T-CELL EPITOPS AND USE THEREOF
US20140286983A1 (en) * 2011-10-20 2014-09-25 The Government of the USA as represented by the Secretaryof the Dept. of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
WO2014064943A1 (en) * 2012-10-25 2014-05-01 Osaka University Antigenic peptide derived from dengue virus
CN110734500A (zh) * 2013-06-26 2020-01-31 北卡罗来纳-查佩尔山大学 用于登革病毒疫苗的方法与组合物
WO2015139784A1 (en) * 2014-03-18 2015-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
SG11201706342PA (en) * 2015-02-09 2017-09-28 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
BR112018075513A2 (pt) * 2016-06-13 2019-10-01 Us Health ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
WO2018052549A1 (en) 2016-09-19 2018-03-22 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
KR102832926B1 (ko) * 2017-04-26 2025-07-10 에프. 호프만-라 로슈 아게 가용성 및 면역반응성 지카 바이러스 ns1 폴리펩티드
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
MX2023004087A (es) * 2020-10-07 2023-09-15 Sanofi Pasteur Pruebas diagnósticas mejoradas.
US12196755B2 (en) 2021-12-02 2025-01-14 Zymeron Corporation Immunoassay platform for the serological discrimination of closely related viruses
US20250188130A1 (en) * 2022-03-17 2025-06-12 The University Of North Carolina At Chapel Hill Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172110B1 (da) 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
WO1998013500A2 (en) * 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
US7622113B2 (en) * 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus

Also Published As

Publication number Publication date
US20110059131A1 (en) 2011-03-10
CA2576798C (en) 2014-09-09
EP1784487A2 (en) 2007-05-16
WO2006025990A3 (en) 2006-06-29
US20080248064A1 (en) 2008-10-09
US20150246951A1 (en) 2015-09-03
US9000141B2 (en) 2015-04-07
US9650422B2 (en) 2017-05-16
CA2576798A1 (en) 2006-03-09
WO2006025990A2 (en) 2006-03-09
ATE521627T1 (de) 2011-09-15
US7906292B2 (en) 2011-03-15
EP1784487B1 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
IN2012DN03294A (cs)
ZA200803012B (en) Bitumen composition
HRP20190220T1 (hr) Anti-il-23 protutijela, pripravci, postupci i upotrebe
NZ581470A (en) Sequence based engineering and optimization of single chain antibodies
MX2020001944A (es) Poblaciones de celula madre de la placenta.
IL195338A0 (en) Optimized fc variants and methods for their generation
MY163480A (en) Sclerostin binding agents
AR060583A1 (es) Anticuerpo de c- kit humanizado
WO2009149956A3 (en) Fusion protein and use thereof
TW200723252A (en) Information processing device, information recording medium manufacturing device, information recording medium, methods thereof, and computer program
TW200701019A (en) Device specific content indexing for optimized device operation
AU2019268061A1 (en) Placental stem cell populations
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
TW200617369A (en) Method to inspect a wafer
TW200720170A (en) Work transfer system
WO2006134190A8 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
UA88308C2 (ru) Агент образования олеогеля, который содержит тритерпен, олеогель и способ его получения
WO2006135793A3 (en) Protein engineering with analogous contact environments
MX2008009830A (es) Efecto del inhibidor bst2.
WO2005116252A3 (en) Methods for evaluating ribonucleotide sequences
MXPA05011410A (es) Tratamiento de incontinencia con agonistas de 5htc2.
ATE467128T1 (de) Kolloidale metallkonjugate
TW200626128A (en) Materials and methods for improving shellfish health, immunity and growth
IL191782A0 (en) Method for generating dendritic cells employing decreased temperature
EA200970074A1 (ru) Химический способ создания давления